EMA Partners on Five-Year Program to Monitor Vaccine Risks, Benefits

International Pharmaceutical Regulatory Monitor
A A
The European Medicines Agency has launched a collaborative five-year program with the goal of developing a blueprint for a pan-European framework for monitoring the benefits and risks of vaccines throughout their lifecycles.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00